Aptar has entered into an enterprise agreement with Biogen Inc. (Nasdaq: BIIB) to operate and develop digital health solutions for neurological and rare diseases. As part of the agreement, Biogen will transfer ownership of select digital health solutions to Aptar Digital Health (Aptar).
Through this collaboration, Aptar will provide a full range of capabilities including the product management, design, development and maintenance of software applications, secured cloud hosting, and customer and marketing support to Biogen.
- New partnership model leverages Aptar Digital Health’s capabilities to support the development and operation of new and existing digital health solutions globally
- Initial scope of multi-year agreement covers several indications in neurology and immunology across 15 countries
Over the past years, Biogen has successfully launched several flagship digital health solutions which have supported hundreds of thousands of patients in over 15 countries. The first solutions to transition to an operation by Aptar in North America, Europe/UK, Asia-Pacific and Latin America are:
- Cleo™/Aby™: a digital care companion app to help people live with multiple sclerosis. It includes disease information, symptom-tracking, treatment reminders and tailored self-care programs on topics like fatigue and emotional management.
- Physio.me: a digital exercise companion that offers at-home, tailored exercises to patients with neuromuscular disorders who can measure and share their progress with their care team and can increase their likelihood to achieve their physical goals.
In addition to these solutions, Biogen and Aptar will further collaborate to potentially develop and bring to market new digital health solutions for the management of spinal muscular amyotrophy, Friedreich’s ataxia and lupus in selected countries.
“We are excited to leverage our end-to-end capabilities to support Biogen and enable patients and their care teams to benefit from advanced digital solutions for better disease management,” said Pierre Leurent, President, Aptar Digital Health. “With this new agreement, Aptar Digital Health’s activities are significantly expanding in neurology and immunology, two strategic therapeutic areas. We look forward to an exciting collaboration between both our groups in the coming years.”
“Biogen is a recognized pharmaceutical leader who has been at the forefront of digital health in neuroscience over the past years,” stated Gael Touya, President, Aptar Pharma. “This flagship collaboration is an excellent illustration of Aptar’s expanding role as a go-to partner for the pharmaceutical industry, offering a comprehensive portfolio of device solutions, services and digital to help improve the lives of patients around the world.”
